TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01809886
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
Study: NCT01809886
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
Study: NCT00420381
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1125 mg loading dose then 500 mg, oral, daily, until progressive disease
Study: NCT01201551
Drug: Brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
Study: NCT01201551
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
Study: NCT01428219
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
Study: NCT02479880
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg tablet administered orally once daily for up to 96 weeks
Study: NCT01333410
Drug: tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 applications per days for 6 months
Study: NCT01333410
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 applications per day for 6 months
Study: NCT01144143
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the study drug will be injected into the joint through a needle
Study: NCT00355368
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg iv
Study: NCT00355368
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6mg/kg iv
Study: NCT00263003
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01435174
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of two oral ranolazine extended release 500 mg tablets
Study: NCT00512278
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
Study: NCT00901225
Drug: G-CSF plus Plerixafor
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.
Study: NCT04884503
Drug: Clonazepam tablets
Normalized name: Clonazepam Tablets
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
Study: NCT02307240
Drug: CUDC-907
Normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 oral with meals.
Study: NCT02171026
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02171026
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01448538
Drug: Anti-VEGF injections
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All Anti-VEGF injections approved for the German market, dosages as defined by doctors
Study: NCT01452477
Drug: tanshinone
Normalized name: Tanshinone A
DrugBank: Cryptotanshinone (DB15579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Study: NCT02869165
Drug: Conjugated equine estrogen topical cream
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Study: NCT02869165
Drug: Apricot kernel oil
Normalized name: Apricot kernel oil
DrugBank: Apricot kernel oil (DB14324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Study: NCT03389308
Drug: diacerein 1% ointment
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically apply study medication to lesions identified by the Investigator that require.~treatment
Study: NCT04414540
Drug: Metformin Extended Release Oral Tablet
Normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
Study: NCT04414540
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab q 3 weeks
Study: NCT02261207
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
Study: NCT00286897
Drug: E2007
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00573391
Drug: Velcade, Thalidomide, and Dexamethasone
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles
Study: NCT00573391
Drug: Velcade, Melphalan, and Dexamethasone
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles
Study: NCT04470297
Drug: Ramelteon 8mg
Normalized name: RAMELTEON 8MG TAB
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
Study: NCT00871663
Drug: SCH 727965
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT02930707
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
Study: NCT02930707
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
Study: NCT02607124
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03294395
Drug: Ertapenem 1000 MG
Normalized name: ertapenem 1000 MG
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose 1000mg intramuscular injection
Study: NCT03294395
Drug: Fosfomycin Oral Suspension
Normalized name: fosfomycin Oral Suspension
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose 6g oral suspension
Study: NCT02770027
Drug: Intravenous Crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT02770027
Drug: Intravenous HES
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT01913847
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sildenafil 20 mg TID for 12 weeks
Study: NCT01118780
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by mouth, daily for 10 weeks
Study: NCT00870480
Drug: Finasteride 5 mg Tablet, single dose
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
Study: NCT02864264
Drug: BMS-986184
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03294395
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose 500mg intramuscular injection
Study: NCT00705874
Drug: CGC-11047 and gemcitabine
Normalized name: CGC-11047
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
Study: NCT00705874
Drug: CGC-11047 and docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
Study: NCT00705874
Drug: CGC-11047 and bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study: NCT00705874
Drug: CGC-11047 and erlotinib
Normalized name: CGC-11047
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study: NCT00705874
Drug: CGC-11047 and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study: NCT00705874
Drug: CGC-11047 and sunitinib
Normalized name: CGC-11047
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
Study: NCT02326727
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural analgesia
Study: NCT02326727
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General Anesthesia
Study: NCT02326727
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General Anesthesia
Study: NCT02326727
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General Anesthesia
Study: NCT01459666
Drug: Dysport (abobotulinumtoxinA)
Normalized name: Dysport
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular injection effects lasting up to 3 months
Study: NCT01459666
Drug: Bacteriostatic 0.9% Sodium Chloride (vehicle)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT00724100
Drug: ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
Normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
Study: NCT01929200
Drug: 1-year treatment with icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
Study: NCT01929200
Drug: 2-year treatment with icotinib
Normalized name: miconazole
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
Study: NCT04169464
Drug: Sofosbuvir Oral Product
Normalized name: sofosbuvir Oral Product
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to investigate the drug effect on renal function and insulin resistance
Study: NCT00533429
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
Study: NCT00533429
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Study: NCT00533429
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study: NCT00533429
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study: NCT02072954
Drug: Asenapine Sublingual Tablets 10 mg
Normalized name: asenapine Sublingual Tablet
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
Study: NCT02072954
Drug: Asenapine Sublingual Tablets 10 mg
Normalized name: asenapine Sublingual Tablet
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Round, white to off-white sublingual tablets, with 10 on one side within a circle
Study: NCT00202696
Drug: nalmefene
Normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
Study: NCT03809273
Drug: Trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20mg/tid
Study: NCT03809273
Drug: Yangxinshi mimic
Normalized name: Bfkb-8488a (bispecific antibody designed to mimic the metabolic hormone fgf21).
DrugBank: Fazpilodemab (DB18924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi mimic tablets 3 pills /tid
Study: NCT03809273
Drug: Trimetazidine mimic
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine mimic tablets 20mg/tid
Study: NCT00602524
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00816075
Drug: distilled water
Normalized name: Distilled Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
Study: NCT02512380
Drug: Docetaxel;oxaliplatin;s1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
Study: NCT02512380
Drug: oxaliplatin;s1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
Study: NCT00233532
Drug: Trandolapril
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
Study: NCT02569346
Drug: Triumeq
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose Triumeq as a whole tablet
Study: NCT02569346
Drug: Triumeq crushed + breakfast
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose crushed and suspended tablet of Triumeq
Study: NCT02569346
Drug: Triumeq crushed + drip feed
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq
Study: NCT02717325
Drug: Coppertone (BAY987517)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
Study: NCT03738722
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
Study: NCT02592421
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SGLT2 inhibitor (dapagliflozin)
Study: NCT03506620
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
Study: NCT01979679
Drug: Lurasidone 80 mg
Normalized name: lurasidone 80 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01979679
Drug: Lurasidone 120 mg
Normalized name: lurasidone 120 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01979679
Drug: Lurasidone 160 mg
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00509327
Drug: bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg capsule twice daily from one day preoperatively to day three postoperatively
Study: NCT02449941
Drug: PPI (proton pump inhibitor)
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI.
Study: NCT03111212
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost nebulized
Study: NCT03111212
Drug: control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium chloride 0,9% nebulized
Study: NCT02739958
Drug: Propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
Study: NCT02739958
Drug: Isoflurane group
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments